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Biphasic test (with apparatus Eur. Ph. type II)  
The European Pharmacopeia (Eur. Ph.) describes four different testing apparatus for solid oral dosage forms and recommends to work 
under sink conditions. However, these conditions are not always discriminant or bio-relevant. The three main reasons are that the 
conventional media used in these tests have a little relevance to the in vivo situation, that phenomena of supersaturation or precipitation 
that can happen in vivo and that the solubility/permeability balance present in vivo are not taken into account. BCS class II Active 
Pharmaceutical Ingredients (API) present a good permeability but a poor oral bioavailability due to insufficient dissolution throughout the 
gastrointestinal tract. Maintaining sink conditions can be problematic for these compounds. To afford these conditions, several solubility 
modifiers should be added to dissolution media. However, the use of these additives is accompanied by inherent disadvantages. One 
emergent and attractive technique used to avoid solubility modifiers adding is the use of biphasic dissolution systems. This model is based 
on the fact that the presence of an upper organic phase within the aqueous dissolution medium could act as a reservoir for dissolved drug. 
In this way, the API, following initial aqueous dissolution, partitions into the organic layer, exploiting the lipophilicity of the compound. 
Fig. 3. Modified apparatus Eur. Ph. type II 
(Paddle apparatus) with a dual paddle 
Fig. 6. Biphasic dissolution test on pure API (capsules) with apparatus Eur. Ph. Type II 
Fig. 7. Apparatus Eur. Ph. type IV combined to our 
modified apparatus Eur. Ph. type II 
Fig. 9. Biphasic dissolution test on PGSS production with 
apparatus Eur. Ph. Type II combined to type IV 
Fig. 8. Biphasic dissolution test on pure API (capsules) 
with apparatus Eur. Ph. Type II combined to type IV Fig. 10. Biphasic dissolution test on market product with 
apparatus Eur. Ph. Type II combined to type IV. 
Fig. 2. Eur.Ph. apparatus type IV 
(Flow-through cell) 
Fig. 1. Biopharmaceutics classification system (BCS) 
A biphasic dissolution test was compared with two single phase dissolution tests: one under sink conditions and another under non-sink conditions. This comparison was done for three different 
formulations of the same BCS II drug: pure API capsules, an improved bioavailability formulation available on the market and a PGSS lipid-based formulation with Gelucire® 50/13 (Gattefossé, 
France). For each test, three replicates were done and all samples were analyzed by a validated HPLC method. 
A dissolution apparatus Eur.Ph. type IV (Fig.2) was used for both tests (sink and non-sink conditions). For the test under non-sink conditions the aqueous 
medium used was HCl 0,1 M.  A surfactant (polysorbate 80) was added at the concentration of 1% to this medium for the test under sink conditions. 
The biphasic dissolution system consisted of an aqueous phase (HCl 0,1 M) with an upper organic phase (octanol). The first test 
was performed in a slightly modified apparatus Eur.Ph. type II. A second paddle was added for the organic phase agitation. 
Test under sink conditions Test under non-sink conditions 
The pure API showed better drug release profile than the others formulations. However, 
for the market product, the bioavailability enhancement has been demonstrated in 
clinical studies. Therefore, this test seems to be discriminating but not bio-relevant. 
The test under non-sink conditions allowed to show an slight increase of the 
saturation concentration of API induced by the formulation with Gelucire® (PGSS 
in Fig.5). However, a complete API dissolution was never reached in these 
conditions. Thus it is difficult to accurately evaluate the rate of the drug release 





















0 30 60 90 120 150 180 210 240 270 300 330 360
% dissolved 
Time (min) 
Biphasic test (with apparatus Eur. Ph. type II combined to type IV)  
The first biphasic test was performed on the pure API capsules. As it can be seen in Fig.6, the concentration in the aqueous phase was almost undetectable while, the concentration in the 
organic phase increased quickly. In fact, due to their hydrophobic nature, the undissolved particles rise to the interface of the two phases and dissolve in the organic solvent. Therefore, the 
concentration in the organic phase was no longer dictated by the drug dissolved in the aqueous phase. This test was not relevant and we had to modify it. 
The modification that we did was to combine the apparatus Eur. Ph. type IV to our modified apparatus Eur. Ph. type II. In this way, the undissolved API particles remain trapped in the dissolution 
cell and can not rise to the organic phase. 
For pure API, the concentration in the aqueous phase 
was always very low and corresponded to saturation 
concentration (CS) in this medium. In the organic 
phase, the concentration was also very low but it 
increased continuously due to the transfer of 
dissolved API from aqueous phase. 
The PGSS formulation showed higher API concentrations in the 
aqueous medium (Cmax) as compared to the CS found in the same 
medium after a saturation step with octanol. This suggests that a 
supersaturation of API due to the type of formulation can be 
detected by this dissolution test thanks to the presence of the 
organic phase. 
The market product showed similar API concentrations in the 
aqueous medium as compared those observed in the single 
phase dissolution test under non-sink conditions (= CS). This 
suggests that this formulation does not allow the establishment 
of a supersaturation during dissolution. However, it allows a 
faster transfer of dissolved API from aqueous phase to organic 
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Given these results, we can conclude that the test under sink conditions seems to be a poor bio-relevant test. In the test under non-sink conditions, the medium is rapidly saturated limiting the 
dissolution process. And finally, a complete dissolution of the API is possible in a biphasic test due to the continuous extraction of the dissolved drug from the aqueous phase into the organic phase. 
Furthermore, the biphasic in vitro test method appears to be a useful tool for the performance evaluation of formulations containing poorly water-soluble drugs, especially if they lead to in vivo 





Fig. 4. Single phase dissolution test under sink conditions 
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